Managing Tardive Dyskinesia: Clinical Pointers

<p>Today's episode is about the management of tardive dyskinesia.</p> <p>Here are some questions we cover in this episode:</p> <ul> <li> What is the best way to approach tardive dyskinesia? This episode will discuss an algorithm with levels of evidence for each treatment option.</li> <li>What is the evidence level for second-generation VMAT-2 inhibitors, such as deutetrabenazine and valbenazine?</li> <li>Is there evidence for prescribing anticholinergics in tardive dyskinesia? Should you use them?</li> <li>What options do you have if a VMAT inhibitor is not effective or well tolerated?</li> </ul> <p>Faculty: Greg Pontone, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC058"> Learn more about Premium Membership here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/drug-induced-movement-disorders-the-clinical-essentials-2557?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC058"> Earn 1.25 CMEs: "Drug-Induced Movement Disorders: The Clinical Essentials"</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/treating-tardive-dyskinesia-a-clinical-conundrum-and-new-approaches-2557-4810?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC058"> Treating Tardive Dyskinesia: A Clinical Conundrum and New Approaches</a></strong></li> </ul> <p> </p>